NeuroPace (NPCE) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Executive introductions

• CEO has over 25 years in medical device leadership and joined just over a year ago.

• CFO has been with the company since its founding, with prior med tech startup experience.

Company mission and technology

• Focused on transforming care for patients with drug-resistant epilepsy.

• Developed RNS, a responsive neuromodulation system for adults with focal epilepsy.

• RNS monitors, records, and analyzes brain activity to tailor therapy.

• Indicated for patients who have failed two or more anti-seizure medications.

• Ongoing research aims to expand indications.

Market and treatment paradigm

• First-line epilepsy treatment is medication; RNS is for those unresponsive to drugs.

• RNS is used after comprehensive diagnostic testing confirms focal seizures.

• Therapy is delivered by a team of epileptologists and neurosurgeons.